San Diego

Cloudbeds Horizon launches to empower hospitality schools to upskill students in cloud technology

Retrieved on: 
Wednesday, December 8, 2021
University, GLOBE, Technology, Bumrungrad International Hospital, Automation, Learning, Curriculum, EHL, Discovery, CEO, Industry, Â, Partnership, VP, SAN, School, Student, Medicine

Cloudbeds Horizon launches following a successful pilot program with EHL , the worlds most prestigious hospitality management school.

Key Points: 
  • Cloudbeds Horizon launches following a successful pilot program with EHL , the worlds most prestigious hospitality management school.
  • Cloudbeds Horizon partners with hospitality schools and universities worldwide to provide access to its innovative cloud software, knowledge base, and on-demand educational materials to help upskill students in modern cloud software and technology.
  • For the EHL pilot, Cloudbeds partnered with the universitys hospitality technology class to develop a weeklong curriculum for students to gain experience managing test properties through the Cloudbeds Hospitality Platform.
  • Cloudbeds Horizon is now available to any hospitality education program worldwide, with universities receiving special educational licenses for students to learn directly on the Cloudbeds Hospitality Platform .

Bionano Genomics Announces Publication of Study Evaluating Optical Genome Mapping for High Throughput Characterization of Cytogenomic Heterogeneity in MDS

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, American Society of Hematology, FISH, Medicine, Company, Monroe Dunaway Anderson, Karyotype, Research, GLOBE, Forward-looking statement, TP53, Security (finance), CMA, Private Securities Litigation Reform Act, TET2, SV, DRS, Bone marrow, Patient, Software, Biomarker, Hospital Insurance and Diagnostic Services Act, Autism, MD Anderson Cancer Center, Method, OGM, Lineagen, MECOM, COVID-19, MDS, Adoption, University, SVS, KMT2A, Diagnosis, Doctor of Philosophy, Solution, CK, Genomics, Biology, Genome, Annual report, SAN, Society, Myelodysplastic syndrome, ASH, Algorithm, Medical imaging, Medical device

The study evaluated the utility of OGM as an alternative to traditional cytogenomic methods for the characterization of structural variation (SV) in myelodysplastic syndrome (MDS).

Key Points: 
  • The study evaluated the utility of OGM as an alternative to traditional cytogenomic methods for the characterization of structural variation (SV) in myelodysplastic syndrome (MDS).
  • MDS refers to disorders of the bone marrow in which it does not produce enough healthy blood cells.
  • Dr. Rashmi Kanagal-Shamanna from MD Anderson commented: The results of this study underscore the potential of optical genome mapping to become a single-platform cytogenetic tool for structural variant profiling in indications such as MDS.
  • Structural variant profiling is as important as sequence variant or mutation profiling for proper characterization of MDS in research and patient management.

Beam Global Announces Expansion of EV ARC™ Fleet in a Federally Funded Research and Development Center

Retrieved on: 
Wednesday, December 8, 2021
General Services Administration, United States national laboratories, Environment, Twitter, Beam Suntory, Forward-looking statement, GLOBE, Budget, Technology, YouTube, DOE, Ministry of Energy, EV, Education Development Center, Phrase, EVSI, Federally funded research and development centers, Gasoline, EVS, Lawrence Livermore National Laboratory, Idaho, Government, NEVS, Sandia National Laboratories, Contract, GSA, National Renewable Energy Laboratory, Federation, Electricity, LinkedIn, Clean technology, ARC, Nasdaq, MAS, Solution, Idaho National Laboratory, SAN, Federal government of the United States, Renewable energy

The EV ARC system is equipped with a dual port charging station to serve the growing fleet of electric vehicles at the facility.

Key Points: 
  • The EV ARC system is equipped with a dual port charging station to serve the growing fleet of electric vehicles at the facility.
  • The EV ARC is transportable and can be relocated as EV fleet charging patterns emerge and grow.
  • Executive Order 14008 has created a sense of priority and urgency in accelerating fleet electrification in federal and federally funded agencies, said Beam Global CEO Desmond Wheatley.
  • For more information on purchasing Beams EV ARC ready-to-deploy sustainable EV charging solutions through the GSA MAS Contract, please contact The Beam Team at 858-799-4583 or [email protected] .

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

Retrieved on: 
Tuesday, December 7, 2021

Today, approximately half of the women treated for bacterial vaginosis experience a recurrence within 12 months of treatment.

Key Points: 
  • Today, approximately half of the women treated for bacterial vaginosis experience a recurrence within 12 months of treatment.
  • XACIATO is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.
  • XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.
  • Indication: XACIATO (clindamycin phosphate) vaginal gel is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Knee pain, Risk, Forward-looking statement, Scoville scale, GLOBE, Patient, Security (finance), Pain, Safety, MTD, Private Securities Litigation Reform Act, RTX, Injection, Walking, Therapy, Vaccine, Index (publishing), Cancer, Osteoarthritis, WOMAC, Antibody, A1, Trigeminal neuralgia, Knee, Time, Trial of the century, Sciatica, Autoimmune disease, Observation, FDA, SAN, Annual report, OA, Capsaicin, TRPV1, Pharmaceutical industry, Generic drug

A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients.

Key Points: 
  • A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients.
  • SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA) has begun enrollment.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.

Challenged Athletes Foundation (CAF) Supports Top Adaptive Surfers from Around the World

Retrieved on: 
Tuesday, December 7, 2021
Finger, Challenged Athletes Foundation, Foot, CA, Carbon, GLOBE, LIV, Alcina, Health, ISA, Business, Parent, Love, Quality of life, Athlete, Surfing, Para, Paralympic Games, Insurance, Leg, Arm, Physical, Travel, CAF, SAN, Entertainment, Sports equipment

Sam Bloom - Palm Beach, New South Wales, Australia -- Australia’s two-time Para Surfing World Champion Sam Bloom is looking to bring home her 3rd world title in adaptive surfing.  In 2013, the Australian nurse became paralyzed from the chest down after falling through a faulty lookout railing on a family vacation. Returning to surfing and reconnecting with her love for the ocean has played a huge role in her health and well-being.

Key Points: 
  • CAF provided 39 travel grants to athletes participating from 15 different countries totaling more than $50,000 of support to advance adaptive surfing.
  • Now, 51 he holds two world titles and owns an adaptive surf school while coaching up and coming adaptive surfers in the North Shore.
  • This year, CAF has funded close to $70,000 total to 57 adaptive surfers globally for surf-related grants including adaptive equipment, coaching and competition travel.
  • The Challenged Athletes Foundation (CAF) is a world leader in helping people with physical challenges lead active, healthy lifestyles.

Sorrento Therapeutics’ Clinical Laboratory Receives Accreditation From the College of American Pathologists

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Pathology, Risk, READ, Forward-looking statement, Accreditation Committee of Cambodia, GLOBE, Medicare, Federation, Security (finance), Accreditation, Pain, Private Securities Litigation Reform Act, RTX, Patient, Therapy, Vaccine, Cancer, Osteoarthritis, College, Antibody, Certification, Trigeminal neuralgia, Trial of the century, Sciatica, Autoimmune disease, Medicaid, FDA, CLIA, National Accreditation Program for Rectal Cancer, SAN, Annual report, CAP, Marie Cassidy, TRPV1, Pharmaceutical industry, Generic drug

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrentos Clinical Laboratory, located in San Diego, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.

Key Points: 
  • SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrentos Clinical Laboratory, located in San Diego, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
  • Sorrentos clinical laboratory was advised of this national recognition and congratulated for the excellence of the services being provided.
  • Additionally, with the CLIA certification and CAP accreditation of its clinical laboratory, Sorrento has the capability to conduct timely clinical studies to support its product pipeline across all stages.
  • As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

The Odor Doctors Announces Partnership with HBCU Legacy Bowl

Retrieved on: 
Tuesday, December 7, 2021
Motivation, HBCU, HBCU Legacy Bowl, Yulman Stadium, Super Bowl, Parent, Historically black colleges and universities, Super Bowl Most Valuable Player Award, Black College Football Hall of Fame, History of the San Diego Chargers, Grambling State University, NFL, Houston Texans, University of Kansas, University, Tulane University, Athlete, Fisk University, San Diego, Partnership, Senior, LLC, NFL Network, History of the Houston Texans, State university system, Marketing, City, Management

HOUSTON, Dec. 7, 2021 /PRNewswire/ -- The Odor Doctors, the premier vehicle odor extraction company in the U. S. is pleased to announce its partnership with the HBCU Legacy Football Game to be hosted by Tulane University, Yulman Stadium, February 19, 2022, in New Orleans, La.

Key Points: 
  • HOUSTON, Dec. 7, 2021 /PRNewswire/ -- The Odor Doctors, the premier vehicle odor extraction company in the U. S. is pleased to announce its partnership with the HBCU Legacy Football Game to be hosted by Tulane University, Yulman Stadium, February 19, 2022, in New Orleans, La.
  • Mark Simmons, Senior Vice-President of The Odor Doctors and a former NFL player, discusses the motivation behind his family's decision to be a sponsor.
  • Today, Mark is the Senior Executive for Marketing By Zip, LLC, parent company of The Odor Doctors and Expertly Sanitized.
  • Among his other outstanding accomplishments are:
    The Odor Doctors, a minority-owned enterprise, is the premier vehicle odor extraction company in the United States.

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Retrieved on: 
Tuesday, December 7, 2021
Company, Research, GLOBE, Precision medicine, SEC, Systemic scleroderma, FVC, Mortality, Therapy, Pharmacokinetics, Vital capacity, MAD, Degenerative disease, Mab, Inflammation, Diffusion, ATHENA, Safety, Ulcer, Private Securities Litigation Reform Act, HRCT, Pulmonary fibrosis, Skin, Inflammatory bowel disease, News, Patient, CEO, TNF, Â, SAD, American College, Disease, ADAS, Ulcerative colitis, COVID-19, IBD, Immunoglobulin G, United, NASDAQ, SAN, Scleroderma, PD, TL1A, Q&A, UC, Fibrosis, Pharmaceutical industry, Vaccine

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results from its Phase 1 trial of PRA023 in healthy volunteers. It also announced that it is broadening its pipeline by adding a third indication for PRA023, Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), with the initiation of a Phase 2 clinical trial anticipated for the first quarter of 2022.

Key Points: 
  • Our design objective for PRA023 was to develop a competitive anti-TL1A antibody, said Mark McKenna, CEO and Chairman of Prometheus Biosciences.
  • The primary outcome measure was safety and tolerability over 14 weeks in the SAD and 18 weeks in the MAD.
  • Prometheus is developing PRA023 for the treatment of immune-mediated diseases including Ulcerative colitis (UC), Crohns disease (CD), and the newly identified systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • The inclusion of forward-looking statements should not be regarded as a representation by Prometheus that any of our plans will be achieved.

Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board

Retrieved on: 
Monday, December 6, 2021

SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced it has appointed Joseph A. Bellanti, M.D. to its scientific advisory board.

Key Points: 
  • We have seen so many advancements and innovations in this area, but still have a long way to go.
  • The work Revelation Biosciences is doing could change the way we look at, prevent and treat stubborn and recurring infections, like influenza and COVID-19.
  • Dr. Bellanti represents the triple threat academician; hes proficient in teaching, research, and patient care, said James Rolke, Chief Executive Officer of Revelation.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.